



## ASX ANNOUNCEMENT

### Simavita successfully completes \$2,920,000 capital raising

**For Immediate Release:**

**26 February 2020**

**Sydney, Australia** – Simavita Limited (ASX: SVA), a global leader in smart wearable technology for the USD64bn adult and infant diaper industry, announced today that it has successfully completed a \$2,920,000 capital raising via a placement to new and existing sophisticated investors.

Proceeds will be used to advance commercialisation activities in key North American and European markets and for working capital. Importantly, funds will be used in corporate restructuring activities.

The placement will result in the issue of 146million new fully-paid CHESS Depository Interests (CDIs) at an Issue Price of A\$0.02 per CDI. The Board considered a Private Placement as the best method for raising funds in the time frame required and to achieve funding certainty.

The Issue Price of \$0.02 per new CDI is equivalent to the last closing price of \$0.02 on 21 February 2020 or a discount of 12.6% to the 15-day volume weighted average market price leading up to 21 February 2020.

Simavita Chairman Mr Michael Spooner said “We’re pleased with strong support from new and existing shareholders. Demand for CDIs significantly exceeded initial placement forecasts. These funds will enable the Company to significantly advance its commercialization strategy and to put in place plans associated with a reorganisation of the Company structure.”

Key terms of the Private Placement:

- A private placement of 146,000,000 CDIs for a total of \$2,920,000 with sophisticated investors at an offer price of \$0.02 per new CDI, represented by:
  - \$1,895,000 representing 94,750,000 CDIs from existing shareholders and sophisticated investors, referred to as Tranche 1 and:
  - \$1,025,000 representing 51,250,000 CDIs from related parties and are subject to shareholder approval, referred to as Tranche 2.
  - The CDIs issued under the Tranche 1 Placement represent 20.3% of the total number of CDIs currently on issue. The new CDIs will rank equally with existing CDIs. The CDIs will be issued and quoted on the ASX on 26 February 2020.
  - Shareholder approval is required for the Tranche 2 Placement. The Company will also take the opportunity to refresh its placement capacity at a Special General Meeting to be held in early April 2020 and to approve the Tranche 2 Placement.
- Capacity for the placement was as follows:
  - 52,972,187 CDIs pursuant to the Company’s ASX Listing Rule 7.1;
  - 41,777,813 CDIs pursuant to the Company’s ASX Listing Rule 7.1A;
  - 51,250,000 CDIs pursuant to ASX Listing Rule 10.11, with:

- 13,750,000 CDIs in total to be issued to Dussman Pty Ltd (an entity associated with Mr Damien Haakman, a Director of the Company); and
- 25,000,000 CDIs to be issued to Thirty Fifth Celebration Pty Ltd ATF JC McBain Super Fund (an entity associated with Dr John McBain, a Director of the Company), both related parties.
- 12,500,000 CDIs to be issued to Fifty Second Celebration Pty Ltd, ATF the McBain Family Trust (an entity associated with Dr John McBain, a Director of the Company), (all related parties).
- The Company is in ongoing discussions with a number of significant companies involved in the manufacture and sale of infant diapers and incontinence pads. These discussions are often complex, relate to major installations and may be of varying duration. The Company is committed to informing our shareholders and market should these discussions translate into signed licensing agreements that are material to the Company and its operations.

For further information, please visit the Company's profile on SEDAR ([www.sedar.com](http://www.sedar.com)) or the Company's website ([www.simavita.com](http://www.simavita.com)) or contact the persons listed below.

Ms Peta Jurd  
Chief Commercial Officer

E: [pjurd@simavita.com](mailto:pjurd@simavita.com)  
T: +61 421 466 653  
W: Investor Centre: [Click here](#)

*This ASX announcement was approved and authorised for release by the Board of Simavita Limited.*

## About Simavita

Simavita (ASX: SVA) is a MedTech Company focused on the development of smart, wearable and disposable platform technologies for the health care market.

Our key platform Smartz™ is a highly disruptive technology focused on transforming a traditional “dumb” diaper into a smart device to help parents and carers of both infants and adults.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. [www.simavita.com](http://www.simavita.com)

## Forward-Looking Information

*This document may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.*

*Forward-looking information relates to future events or future performance and reflects Simavita management's expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.*

*In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual*

*results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in*

*obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita's interim and annual financial statements and management's discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.*